Objectives: Antifungal treatment of uncommon filamentous fungal infections is problematic. This study determined the in vitro susceptibility of miltefosine, as a single agent and in combination with posaconazole or voriconazole, against these pathogens.
Introduction
Infections due to uncommon but emerging filamentous fungal pathogens are difficult to treat. Many are resistant/less susceptible to current antifungals. 1 Novel antifungal treatment approaches remain central to improving therapeutic outcomes. Combination antifungal therapy with different, including new, drug classes based on the premise of synergistic effects is one approach used with good clinical response. 2 -4 However, in vitro data identifying effective combinations of antifungals against uncommon filamentous fungi are relatively few.
The antileishmanial agent miltefosine (hexadecylphosphocholine) has fungicidal activity against Scedosporium, Fusarium and the mucormycetes (previously zygomycetes). 5 Here, we investigated the (i) in vitro susceptibility of uncommon filamentous fungi to miltefosine and (ii) potential synergy/additive effects of voriconazole and posaconazole in combination with miltefosine. Voriconazole has activity against certain Fusarium and Scedosporium species, whilst posaconazole is used to treat mucormycoses. 4, 6, 7 Materials and methods 8 and sequencing of the fungal rRNA gene (internal transcribed spacer region and/or 28S ribosomal subunit) 9 or elongation factor 1a gene. 10 A. flavus ATCC 204304 and A. fumigatus ATCC 204305 were the quality control strains in each test run. Inoculum suspensions were prepared according to the CLSI M38-A2 protocol and adjusted to an optical density (at 530 nm) of 0.09-0.13 for A. flavus and 0.15 -0.17 for all other isolates.
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Sensititre testing
MICs of voriconazole and posaconazole (and the other antifungal drugs in this commercial assay) were determined using Sensititre YeastOne plates (YO10; Trek Diagnostic System, ThermoScientific, Australia). 12 
Miltefosine susceptibility testing
Miltefosine (final concentration range 0.5-256 mg/L) MICs were determined according to the CLSI M38-A2 protocol. 11 MICs were read visually after 48-72 h. The MIC was the lowest concentration demonstrating 100% growth inhibition. Minimum fungicidal concentration (MFC) was the lowest drug concentration that showd either no growth or fewer than three colonies to obtain 99%-99.5% killing activity. The MFC was determined by plating 100 mL aliquots from wells with no visible growth (after 48 h incubation) onto Sabouraud's agar and examining for fungal growth after 2-3 days. 5 Each isolate was tested in duplicate in two independent experiments.
Antifungal synergy testing
Twenty isolates (10 mucormycete strains, 8 Fusarium spp. and 2 Scedosporium spp.) were tested using the CLSI chequerboard broth microdilution method. 13 The drug combinations studied were miltefosine/voriconazole and miltefosine/posaconazole. Based on the respective drug MICs for each isolate, the final drug concentration ranges were 0.06 -16 mg/L for posaconazole (0.08-22.8 mM) and voriconazole (0.17-45.8 mM), and 0.06 -64 mg/L (0.14-157 mM) for miltefosine (data not shown). Serial 2-fold dilutions of miltefosine and voriconazole or posaconazole were placed into 96-well plates in a vertical and horizontal direction, respectively. Fifty microlitres of each dilution of the respective drugs were dispensed; 100 mL of inoculum containing 0.4-5×10 4 spores/mL was dispensed into each well.
14 The fractional inhibitory concentration index (FICI) was calculated using the equation (MIC drug A in combination/MIC drug A alone)+ (MIC drug B in combination/MIC drug B alone). FICI values of ≤0.5 were indicative of synergy, values of .4 were indicative of antagonism and values of .0.5-4 were indicative of no interaction. 14 The assay was performed twice for each isolate.
Results
Single drug susceptibilities
The geometric mean (GM) MICs and MIC ranges of miltefosine, amphotericin B, posaconazole, voriconazole, itraconazole, caspofungin and anidulafungin for 34 clinical isolates are shown in Table 1 .
The miltefosine MICs for Aspergillus species were 4-fold higher than those of the other test drugs (GM MIC 5.28 mg/L; Table 1 ). Of 8 Fusarium isolates, Fusarium oxysporum strains had a higher miltefosine GM MIC than Fusarium solani (13.45 versus 8 mg/L; Table 1 ). For Scedosporium apiospermum strains, the GM MIC of miltefosine was similar to that of amphotericin B, but higher than those of voriconazole and posaconazole (Table 1) . Miltefosine had a lower (Table 1) .
For all isolates, the MFCs of miltefosine were the same as the corresponding MICs (data not shown).
Synergy testing
Twenty strains (Table 2 ) with relatively high MICs of miltefosine, posaconazole and voriconazole (Table 1) were chosen for synergy studies. Aspergillus spp. were not further studied as the voriconazole and posaconazole MICs were low.
Synergy of miltefosine with posaconazole was observed for three F. oxysporum strains (isolates CB-9, CB-11 and CB-12; FICIs of 0.37, 0.5 and 0.5, respectively; Table 2 ). The MICs of posaconazole fell 10 -100-fold (from 0.5 to 0.06 mg/L) for strain CB-9 and 4-fold (16 to 4 mg/L) for strains CB-11 and CB-12. Miltefosine and voriconazole were synergistic against one strain of S. prolificans; indifferent effects (FICIs of 1 -2) were generally observed using the miltefosine/azole combinations ( Table 2) .
Miltefosine/posaconazole combinations demonstrated synergy against an L. corymbifera strain, two Rhizopus oryzae isolates and two Mucor isolates (5 of 10 mucormycetes; Table 2 ). For both R. oryzae isolates, the miltefosine MICs were reduced 8 -100-fold and those of posaconazole were reduced 5-10-fold. When miltefosine was tested with voriconazole, isolate R. oryzae CB-30 demonstrated synergy, as did L. corymbifera CB-23 and Rhizomucor sp. CB-32.
No other synergistic combinations were observed and no antagonism was demonstrated for any isolate with either drug combination.
Discussion
Despite the lack of robust supportive data, combination antifungal therapy, which in theory enables each drug to be effective at lower drug concentrations, 2 is increasingly used to treat invasive fungal infections. Here, we show that miltefosine has in vitro activity against Scedosporium spp. and certain mucormycetes. A key finding was the in vitro synergy against 55% of 20 isolates tested, particularly amongst F. oxysporum and mucormycetes, when miltefosine was combined with posaconazole (eight instances) or voriconazole (four instances). The MICs of individual drugs were lowered substantially.
Fusarium spp. are resistant to most antifungals, with reports showing relatively lower MICs of amphotericin B, voriconazole and posaconazole, though susceptibility varies with species. 15 We observed amphotericin B to be the most active agent against both F. oxysporum and F. solani. MICs of 8-16 mg/L (Table 1) suggest Biswas et al.
that miltefosine is an unlikely antifusarial candidate. Against Fusarium spp., data are conflicting regarding synergy between combinations of marketed antifungals, e.g. the azoles and amphotericin B, but may reflect species differences. 14 We observed synergy between miltefosine and posaconazole against three of four F. oxysporum isolates, but not against F. solani. The data suggest that miltefosine/posaconazole combinations have potential for study as a novel treatment for F. oxysporum infections.
S. prolificans is resistant to all licensed antifungal agents, although voriconazole is often incorporated into the antifungal regimen to treat such infections. 7 In the present study, miltefosine MICs for S. prolificans were 2 -4-fold lower than those of posaconazole, voriconazole and itraconazole. We also observed synergy between miltefosine and voriconazole against a single S. prolificans isolate. The combination of voriconazole and terbinafine, which often demonstrate synergy in vitro, has been used successfully to treat S. prolificans infections. 16 Anecdotal reports of success using miltefosine to treat such infections in combination with other antifungals is supported by our finding that certain strains may exhibit synergy with voriconazole. 17 In this study, amphotericin B was the most potent drug against mucormycetes (MICs ,0.5 mg/L for most strains), while posaconazole had the greatest activity amongst the azoles. Amphotericin B formulations are preferred for intensive initial treatment of mucormycosis, with a switch to posaconazole suppressive therapy after an initial clinical response. 4 Although miltefosine MICs were high for most mucormycete isolates, L. corymbifera and a Rhizomucor were more susceptible. Further, azole/miltefosine synergy was observed in seven instances (Table 2) , with 5 of 10 isolates exhibiting posaconazole/miltefosine synergistic interactions and 2 of 10 exhibiting voriconazole/miltefosine synergistic interactions. Interestingly, synergy was seen with the posaconazole/miltefosine combination against both R. oryzae isolates, which demonstrated the highest miltefosine MICs. Given the current uncertainty concerning the in vivo activity of miltefosine, 5, 18 it is important for the in vitro synergy to be replicated by animal and clinical data in order to use the posaconazole/miltefosine combination as an alternative to polyene therapy. This combination approach may alleviate difficulties in achieving target posaconazole blood levels due to variable bioavailability 19 by enabling posaconazole to be effective at lower concentrations.
The mechanism by which miltefosine could synergize with the azoles is uncertain. While the triazoles, posaconazole and voriconazole, inhibit fungal lanosterol 14 a-demethylase, 20 miltefosine, a membrane phospholipid (phosphatidylcholine) analogue, enhances fungal membrane permeability (C. Biswas, unpublished results) and targets fungal phospholipase B1 enzymes and the yeast mitochondrial subunit COX9. 5, 21 The different mechanistic effects of miltefosine and the triazoles on the fungal cell membrane could be exploited in developing future therapeutic strategies. In conclusion, antifungal combinations of posaconazole or voriconazole with the novel antifungal agent miltefosine are synergistic against some strains of drug-resistant fungi, most notably the mucormycetes. These combinations may be of value in clinical therapy.
